Chemomab advances SSc and PSC trials but cash runway shortens to mid-2024

Filed May 11, 2023 · Period ending March 31, 2023 · Compared to 10-Q May 12, 2022 · ~1 min read

Key Changes

• high

  FDA cleared Phase 2 systemic sclerosis trial in February 2023, with enrollment expected midyear and data readout targeted for H2 2024, advancing the company's second lead rare-disease indication.

  MD&A: FDA clearance for SSc Phase 2 trial verify on EDGAR →
• high

  Cash runway extended only six months despite one year passing—now projects funds through June 2024 versus end-2023 previously—signaling higher burn from expanded clinical programs and near-term financing need.

  MD&A: Cash runway projection verify on EDGAR →
• high

  R&D expenses jumped $4.1 million (151%) in Q1 2023 versus prior year, driving net loss to $8.8 million from $5.1 million, as PSC dose-finding, SSc trial launch, and NASH completion accelerated spending.

  MD&A: Research and development expenses verify on EDGAR →